Journal article · 2026

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC

Fei Zhou, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, Yan Yu, Wenxiu Yao, Yun Fan, Xingxiang Pu, Chunling Liu, Jiuwei Cui and 27 more

New England Journal of Medicine · Published 25 October 2026 · DOI 10.1056/nejmoa2611280

View at the publisherCite this paper

In brief

“Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC” is a 2026 journal article by Fei Zhou and 38 co-authors, published in New England Journal of Medicine. OpenAlex counts 2 citations as of 16 November 2026, which puts it in the top 5% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
2
Most cited in
2026 (2)
Field-weighted impact
4.80
References
21
Authors
39

Abstract

BACKGROUND: Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain suboptimal. METHODS: In this phase 3, open-label, randomized trial, we evaluated sacituzumab tirumotecan plus pembrolizumab in… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhou, F., Meng, X., Ding, Q., Zhang, P., Liang, W., Guo, S., Yu, Y., Yao, W., Fan, Y., Pu, X., Liu, C., Cui, J., Chen, P., Zhong, H., Wang, Y., Huang, Z., Xu, Z., Dong, X., Yi, T., . . . Zhou, C. (2026). Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2611280

MLA 9

Zhou, Fei, et al. “Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2611280.

Chicago

Zhou, Fei, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, Yan Yu, et al. 2026. “Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2611280.

Harvard

Zhou, F. et al. (2026) ‘Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC’, New England Journal of Medicine. doi:10.1056/nejmoa2611280.

IEEE

F. Zhou et al., “Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2611280.

BibTeX

@article{zhou2026sacituzumab,
  title     = {{Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC}},
  author    = {Zhou, Fei and Meng, Xiangjiao and Ding, Qingqing and Zhang, Peng and Liang, Wenhua and Guo, Sanxing and Yu, Yan and Yao, Wenxiu and Fan, Yun and Pu, Xingxiang and Liu, Chunling and Cui, Jiuwei and Chen, Peng and Zhong, Hua and Wang, Yongsheng and Huang, Zhangzhou and Xu, Zhi and Dong, Xiaorong and Yi, Tienan and Hu, Ying and Wang, Qiming and Chen, Bolin and Wang, Hui and Sun, Longhua and He, Lang and Zheng, Wei and Wang, Yina and Zhang, Xiaochen and Yao, Yu and Li, Yongsheng and others},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  doi       = {10.1056/nejmoa2611280},
  url       = {https://doi.org/10.1056/nejmoa2611280}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • sacituzumab tirumotecan
  • pembrolizumab
  • non-squamous non-small cell lung cancer
  • first-line therapy
  • immune checkpoint inhibitors
  • chemotherapy
  • progression-free survival
  • overall survival

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Zhou, F., Meng, X., Ding, Q., Zhang, P., Liang, W., Guo, S., Yu, Y., Yao, W., Fan, Y., Pu, X., Liu, C., Cui, J., Chen, P., Zhong, H., Wang, Y., Huang, Z., Xu, Z., Dong, X., Yi, T., . . . Zhou, C. (2026). Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2611280

How many times has this paper been cited?

2 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Fei Zhou, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, Yan Yu, Wenxiu Yao, Yun Fan, Xingxiang Pu, Chunling Liu, Jiuwei Cui and 27 more.

What is the DOI of this paper?

10.1056/nejmoa2611280, permanently at https://doi.org/10.1056/nejmoa2611280. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.